Thinking of Buying BioNTech? Consider These 3 Things First
The coronavirus vaccine race might be over, but that doesn't make BioNTech (NASDAQ: BNTX) any less relevant. With its shares coasting in the aftermath of a decline of more than 15% in the last 12 months, the biotech's next act is already in motion, and it can't arrive soon enough for investors.
But is the stock as good of a buy in 2022 as it was in 2020, or would it be better to wait for it to gain a bit more momentum once again? To answer those questions, let's examine three key things that'll determine the company's future.
Image source: Getty Images.
Source Fool.com
